Trial Profile
A phase 2 study of EKB-569 [pelitinib] in subjects with advanced non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2009
Price :
$35
*
At a glance
- Drugs Pelitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Aug 2009 Actual end date (Jan 2005) and actual patient number (44) added as reported by ClinicalTrials.gov.
- 25 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2005 New trial record.